Key Points
- Insider sale: Director Hanlin Gao sold 535 shares of Fulgent Genetics on Nov. 24 at an average price of $30.47 for $16,301.45, reducing his stake to 954,908 shares (a ~0.06% ownership decrease) after prior sales in August and September.
- Mixed fundamentals: Fulgent reported $0.14 EPS and $84.07M revenue for the quarter, beating estimates, but still has a negative net margin and negative ROE, with FY2025 guidance of 0.30 EPS and analysts forecasting a challenging near-term EPS outlook.
- Market and analyst view: FLGT trades near its 52-week high (~$30.85) with a market cap around $953.6M, and analyst ratings are mixed (two Buys, one Hold, one Sell) producing a consensus rating of "Hold" and a $32 target price.
Fulgent Genetics, Inc. (NASDAQ:FLGT - Get Free Report) insider Hanlin Gao sold 535 shares of Fulgent Genetics stock in a transaction dated Monday, November 24th. The shares were sold at an average price of $30.47, for a total transaction of $16,301.45. Following the sale, the insider owned 954,908 shares in the company, valued at approximately $29,096,046.76. This represents a 0.06% decrease in their ownership of the stock. The sale was disclosed in a filing with the Securities & Exchange Commission, which is available at this hyperlink.
Hanlin Gao also recently made the following trade(s):
- On Wednesday, September 3rd, Hanlin Gao sold 1,063 shares of Fulgent Genetics stock. The shares were sold at an average price of $22.03, for a total transaction of $23,417.89.
- On Wednesday, August 27th, Hanlin Gao sold 943 shares of Fulgent Genetics stock. The shares were sold at an average price of $21.48, for a total transaction of $20,255.64.
Fulgent Genetics Trading Up 0.7%
FLGT stock opened at $30.85 on Wednesday. The firm's 50-day moving average is $24.39 and its two-hundred day moving average is $21.80. The company has a market capitalization of $953.64 million, a price-to-earnings ratio of -18.58 and a beta of 0.92. Fulgent Genetics, Inc. has a 52 week low of $14.57 and a 52 week high of $31.04.
Fulgent Genetics (NASDAQ:FLGT - Get Free Report) last posted its quarterly earnings data on Friday, November 7th. The company reported $0.14 EPS for the quarter, beating analysts' consensus estimates of ($0.22) by $0.36. Fulgent Genetics had a negative net margin of 16.83% and a negative return on equity of 2.26%. The business had revenue of $84.07 million for the quarter, compared to analyst estimates of $81.43 million. Fulgent Genetics has set its FY 2025 guidance at 0.300-0.300 EPS. On average, equities research analysts predict that Fulgent Genetics, Inc. will post -0.85 earnings per share for the current year.
Institutional Inflows and Outflows
Several hedge funds and other institutional investors have recently made changes to their positions in FLGT. Acadian Asset Management LLC raised its position in Fulgent Genetics by 124.0% during the first quarter. Acadian Asset Management LLC now owns 805,941 shares of the company's stock valued at $13,611,000 after buying an additional 446,076 shares during the period. Millennium Management LLC lifted its position in Fulgent Genetics by 28.6% in the 1st quarter. Millennium Management LLC now owns 1,969,433 shares of the company's stock worth $33,283,000 after buying an additional 437,632 shares in the last quarter. JPMorgan Chase & Co. boosted its stake in shares of Fulgent Genetics by 767.0% during the 3rd quarter. JPMorgan Chase & Co. now owns 299,014 shares of the company's stock valued at $6,758,000 after buying an additional 264,524 shares during the period. Diametric Capital LP purchased a new position in shares of Fulgent Genetics during the 2nd quarter valued at $3,359,000. Finally, Cubist Systematic Strategies LLC increased its stake in shares of Fulgent Genetics by 299.4% in the first quarter. Cubist Systematic Strategies LLC now owns 221,221 shares of the company's stock worth $3,739,000 after acquiring an additional 165,828 shares during the last quarter. 48.06% of the stock is currently owned by institutional investors and hedge funds.
Wall Street Analyst Weigh In
FLGT has been the topic of a number of research reports. Raymond James Financial reissued an "outperform" rating and issued a $36.00 price objective on shares of Fulgent Genetics in a research note on Friday, November 14th. Weiss Ratings reiterated a "sell (d-)" rating on shares of Fulgent Genetics in a research report on Wednesday, October 8th. Wall Street Zen raised shares of Fulgent Genetics from a "hold" rating to a "buy" rating in a report on Saturday, November 15th. Piper Sandler raised their price objective on shares of Fulgent Genetics from $21.00 to $30.00 and gave the company a "neutral" rating in a research report on Tuesday, November 11th. Finally, UBS Group upgraded shares of Fulgent Genetics from a "neutral" rating to a "buy" rating and boosted their target price for the stock from $20.00 to $30.00 in a report on Tuesday, August 5th. Two investment analysts have rated the stock with a Buy rating, one has issued a Hold rating and one has given a Sell rating to the company. According to MarketBeat, Fulgent Genetics presently has an average rating of "Hold" and a consensus target price of $32.00.
Check Out Our Latest Stock Report on Fulgent Genetics
About Fulgent Genetics
(
Get Free Report)
Fulgent Genetics, Inc, together with its subsidiaries, provides clinical diagnostic and therapeutic development solutions to physicians and patients in the United States and internationally. The company's clinical diagnostic solutions include molecular diagnostic testing; genetic testing; anatomic pathology laboratory tests and testing services, such as gastrointestinal pathology, dermatopathology, urologic pathology, breast pathology, neuropathology, and hematopathology; oncology tests and testing services; and sequencer services related to hereditary cancer, reproductive health, and other diseases.
Featured Stories
This instant news alert was generated by narrative science technology and financial data from InsiderTrades.com in order to provide readers with the fastest and most accurate reporting. Please send any questions or comments about this story to [email protected].
